Edgar Filing: Pfaffle Antony - Form 4

Pfaffle Ante Form 4	ony									
December (07, 2012									
FORM	A 4 UNITED	STATES					E COMMISSION		PPROVAL	
Check t	his box		Wa	shington	, D.C. 20	549		Number:	3235-0287	
if no lor subject Section Form 4		NGES IN SECUI	Expires: Estimated burden hou response	urs per						
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Pfaffle Antony			2. Issuer Name and Ticker or Trading Symbol CorMedix Inc. [CRMD]				5. Relationship of Reporting Person(s) to Issuer			
			3. Date of Earliest Transaction				(Check all applicable)			
(Last) (First) (Middle) C/O CORMEDIX INC., 745 RT. 202-206, SUITE 303			(Month/Day/Year) 12/05/2012			X Director Officer (giv below)		% Owner her (specify		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
BRIDGEW	VATER, NJ 08807	7					Person	wore than one R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Amount	(D) Price				
Reminder: Re	eport on a separate line	e for each cla	ass of sec	urities bene	-	-	-	ation of a	TEC 1474	
					inforn requi	nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ently valid OMB co	n are not rm	GEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Pfaffle Antony - Form 4

(Instr. 3)	Price of Derivative Security	(1	Month/Day/Year)	(Instr. 8	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	7 (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.68	12/05/2012		A	250,000		<u>(1)</u>	12/05/2022	Common Stock, \$0.001 par value per share	250,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
Pfaffle Antony C/O CORMEDIX INC. 745 RT. 202-206, SUITE 303 BRIDGEWATER, NJ 08807	Х					
Signatures						
/s/ Antony F						

Pfaffle	12/07/2012			
<u>**</u> Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These options vest as follows: fifty-percent (50%) on the date of issuance of the CE Mark approval in Europe for the Company's

(1) Neutrolin(R) product candidate, if the CE Mark approval is obtained on or before March 31, 2013, and fifty-percent (50%) on December 31, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.